Showing 3761-3770 of 5646 results for "".
- Eversight Center Awards 2024 Eye & Vision Research Grantshttps://modernod.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/The Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, recently announced it has awarded four grants to investigators at Tufts University in Boston, Massachusetts; Wayne State University in Detroit, Michigan; and University of Michigan in Ann Arbor, Michigan, to advance prom
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0
- Haag-Streit Launches Eyesi Indirect Ophthalmoscope ROP Simulator for Retinal Examinations on Preterm Infantshttps://modernod.com/news/haag-streit-launches-eyesi-indirect-ophthalmoscope-rop-simulator-for-retinal-examinations-on-preterm-infants/2482200/Haag-Streit has launched the Eyesi Indirect Ophthalmoscope ROP Simulator for training of retinal examinations on premature babies and classification of retinopathy of prematurity (ROP). The high-fidelity training system is designed to allow residents to practice device handling and
- Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implantshttps://modernod.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- Alcon Launches Clareon Presbyopia Correcting IOLs in Indiahttps://modernod.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/Alcon announced the launch of the Clareon family of IOLs in India. Clareon is designed to deliver consistent visual outcomes and exceptional clarity that lasts and is features a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglist